Routine use of intravenous low-dose recombinant tissue plasminogen activator in japanese patients: General outcomes and prognostic factors from the SAMURAI register

Stroke

Volumn 40, Issue 11, 2009, Pages 3591-3595

  Toyoda, Kazunori ^a   Koga, Masatoshi ^a   Naganuma, Masaki ^a   Shiokawa, Yoshiaki ^b,c   Nakagawara, Jyoji ^d   Furui, Eisuke ^e   Kimura, Kazumi ^f   Yamagami, Hiroshi ^g   Okada, Yasushi ^h   Hasegawa, Yasuhiro ⁱ   Kario, Kazuomi ^j   Okuda, Satoshi ^k   Nishiyama, Kazutoshi ^b,c   Minematsu, Kazuo ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b Department of Neurosurgery ^*

^c KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Nakamura Memorial Hospital   (Japan)

^e KOHNAN HOSPITAL   (Japan)

^f KAWASAKI MEDICAL SCHOOL   (Japan)

^g KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^h NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

ⁱ ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j JICHI MEDICAL UNIVERSITY   (Japan)

^k NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

more..

Author keywords

Acute stroke; Alteplase; Cerebral infarction; Recombinant tissue plasminogen activator; Stroke outcome; Thrombolysis

Indexed keywords

ALTEPLASE; ANTIHYPERTENSIVE AGENT; NORPHENAZONE;

AGED; ARTICLE; BRAIN EMBOLISM; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERGLYCEMIA; INTERNAL CAROTID ARTERY OCCLUSION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PRIORITY JOURNAL; RANKIN SCALE; RISK ASSESSMENT; SINGLE DRUG DOSE; STROKE;

AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROGNOSIS; RECOMBINANT PROTEINS; REGISTRIES; RETROSPECTIVE STUDIES; STROKE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 70350528842     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.109.562991     Document Type: Article

References (22)

1. Yamaguchi T, Kikuchi H, Hayakawa T; Japanese Thrombolysis Study Group. Clinical efficacy and safety of intravenous tissue plasminogen activator in acute embolic stroke: a randomized, double-blind, dose comparison study of duteplase. In: Yamaguchi T, Mori E, Minematsu K, del Zoppo GJ, eds. Thrombolytic Therapy in Acute Ischemic Stroke III. Tokyo: Springer-Verlag; 1995:223-229.
2. Yamaguchi T, Mori E, Minematsu K, Nakagawara J, Hashi K, Saito I, Shinohara Y; Japan Alteplase Clinical Trial (J-ACT) Group. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteprase Clinical Trial. Stroke. 2006;37:1810-1815.
3. Nakashima T, Toyoda K, Koga M, Matsuoka H, Nagatsuka K, Takada T, Naritomi H, Minematsu K. Arterial occlusion sites on MRA influence the efficacy of intravenous low-dose (0.6 mg/kg) alteplase therapy for ische-mic stroke. Int J Stroke. 2009;4:In press.
4. Kent DM, Selker HP, Ruthazer R, Bluhmki E, Hacke W. The stroke-thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic stroke. Stroke. 2006;37: 2957-2962.
5. Sylaja PN, Dong W, Grotta JC, Miller MK, Tomita K, Hamilton S, Semba C, Hill MD. Safety outcomes of Alteplase among acute ischemic stroke patients with special characteristics. Neurocrit Care. 2007;6: 181-185.
6. Wahlgren N, Ahmed N, Eriksson N, Aichner F, Bluhmki E, Dávalos A, Erilä T, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Köhrmann M, Larrue V, Lees KR, Machnig T, Roine RO, Toni D, Vanhooren G; Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy Investigators. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST). Stroke. 2008;39:3316-3322.
7. Ahmed N, Wahlgren N, Brainin M, Castillo J, Ford GA, Kaste M, Lees KR, Toni D; SITS Investigators. Relationship of blood pressure, antihy-pertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis. Retrospective analysis from Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register (SITS-ISTR). Stroke. 2009;40:2442-2449.
8. Kimura K, Iguchi Y, Shibazaki K, Terasawa Y, Inoue T, Uemura J, Aoki J. Large ischemic lesions on diffusion-weighted imaging done before intravenous tissue plasminogen activator thrombolysis predicts a poor outcome in patients with acute stroke. Stroke. 2008;39:2388-2391.
9. Guideline Committee for Intravenous rt-PA (alteplase) in Acute Ischemic Stroke. Guidelines for intravenous application of rt-PA (alteplase) [in Japanese]. Jpn J Stroke. 2005;26:327-354.
10. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
11. Barber PA, Demchuk AM, Zhang J, Buchan AM; for the ASPECTS Study Group. Validity and reliability of a semiquantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. Lancet. 2000;355:1670-1674.
12. Barber PA, Hill MD, Eliasziw M, Demchuk AM, Pexman JH, Hudon ME, Tomanek A, Frayne R, Buchan AM; ASPECTS Study Group. Imaging of the brain in acute ischaemic stroke: comparison of computed tomography and magnetic resonance diffusion-weighted imaging. J Neurol Neurosurg Psychiatry. 2005;76:1528-1533.
13. Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Kuelkens S, Larrue V, Lees KR, Roine RO, Soinne L, Toni D, Vanhooren G; SITS-MOST investigators. Thrombol-ysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369:275-282
14. Edaravone Acute Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis. 2003;15:222-229.
15. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA. 2000;283:1145-1150.
16. Hill MD, Buchan AM; Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ. 2005; 172:1307-1312.
17. Ribo M, Molina C, Montaner J, Rubiera M, Delgado-Mederos R, Are-nillas JF, Quintana M, Alvarez-Sabín J. Acute hyperglycemia state is associated with lower tPA-induced recanalization rates in stroke patients. Stroke. 2005;36:1705-1709.
18. Poppe AY, Majumdar SR, Jeerakathil T, Ghali W, Buchan AM, Hill MD; Canadian Alteplase for Stroke Effectiveness Study Investigators. Admission hyperglycemia predicts a worse outcome in stroke patients treated with intravenous thrombolysis. Diabetes Care. 2009;32:617-622.
19. Yong M, Kaste M. Association of characteristics of blood pressure profiles and stroke outcomes in the ECASS-II trial. Stroke. 2008;39: 366-372.
20. Martin-Schild S, Hallevi H, Albright KC, Khaja AM, Barreto AD, Gonzales NR, Grotta JC, Savitz SI. Aggressive blood pressure-lowering treatment before intravenous tissue plasminogen activator therapy in acute ischemic stroke. Arch Neurol. 2008;65:1174-1178.
21. Rubiera M, Ribo M, Delgado-Mederos R, Santamarina E, Delgado P, Montaner J, Alvarez-Sabín J, Molina CA. Tandem internal carotid artery/ middle cerebral artery occlusion: an independent predictor of poor outcome after systemic thrombolysis. Stroke. 2006;37:2301-2305.
22. Saqqur M, Uchino K, Demchuk AM, Molina CA, Garami Z, Calleja S, Akhtar N, Orouk FO, Salam A, Shuaib A, Alexandrov AV; CLOTBUST Investigators. Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke. Stroke. 2007;38:948-954.